InsidersTradesSigma
Abbott Laboratories Stock: price and insider trades · United States · SEC (Form 4)
Track the Abbott Laboratories stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Abbott Laboratories has published 330 insider filings. Market capitalisation: €166.2bn. The latest transaction was reported on 1 July 2026 (Retenue fiscale). Among the most active insiders: Morrone Louis H.. All data is accessible without an account.
330
Insider Decl.
0
Thresholds
€938,338
2 ops.
Buy Volume
€36m
40 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Abbott Laboratories Buy (bullish), based on 25 analysts. Average price target: US$116.72.
51Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 7,208 of 25,535 companies
62.6
score / 100
Value52
Quality73
FCF yld4.4%
Earn yld3.9%
EV/EBITDA15.0x
ROE12%
Gross mgn56%
Net mgn15%
Debt/EBITDA1.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 1 July 2026
Declarations330 total
269 sharesCommon shares without par valueSEC:0001867666-26-000009:0
560 sharesCommon shares without par valueSEC:0002075371-26-000009:0
2,000 shares@ US$86.820.0001% mcap100.0% of flowCommon shares without par valueSEC:0001385262-26-000017:0
Ideal exit: 1 Feb 2027 (T+270)
2,286 shares0Common shares without par valueSEC:0000902132-26-000005:0
10,000 shares@ US$92.65370.0004% mcap4.1% of flowCommon shares without par valueSEC:0000902132-26-000005:1
Ideal exit: 22 Jan 2027 (T+270)
2,286 shares0Common shares without par valueSEC:0001294731-26-000004:0
2,286 shares0Common shares without par valueSEC:0001306119-26-000004:0
2,286 shares0Common shares without par valueSEC:0001385262-26-000012:0
2,286 shares0Common shares without par valueSEC:0001527742-26-000012:0
2,286 shares0Common shares without par valueSEC:0001537286-26-000002:0
2,286 shares0Common shares without par valueSEC:0001577544-26-000006:0
2,286 shares0Common shares without par valueSEC:0001640036-26-000004:0
2,286 shares0Common shares without par valueSEC:0001736637-26-000002:0
2,286 shares0Common shares without par valueSEC:0001787479-26-000003:0
2,286 shares0Common shares without par valueSEC:0001879701-26-000006:0
2,286 shares0Common shares without par valueSEC:0002102715-26-000004:0
8,577 shares@ US$116.265.3% of flowCommon shares without par valueSEC:0001530893-26-000004:0
30,308 shares@ US$116.268.7% of flowCommon shares without par valueSEC:0001612571-26-000006:0
6,615 shares@ US$116.268.0% of flowCommon shares without par valueSEC:0001620564-26-000007:0
885 shares@ US$115.581.1% of flowCommon shares without par valueSEC:0001620564-26-000007:1
1,142 shares@ US$116.2622.7% of flowCommon shares without par valueSEC:0001644207-26-000007:0
585 shares@ US$115.5811.6% of flowCommon shares without par valueSEC:0001644207-26-000007:1
4,997 shares@ US$116.26100.0% of flowCommon shares without par valueSEC:0001772286-26-000004:0
4,630 shares@ US$116.2613.4% of flowCommon shares without par valueSEC:0001783147-26-000007:0
613 shares@ US$115.581.8% of flowCommon shares without par valueSEC:0001783147-26-000007:1
25 of 330 declarations
About Abbott Laboratories
Abbott Laboratories (ticker: ABT) is a global healthcare company listed in the United States on the NYSE/NASDAQ and headquartered in Abbott Park, Illinois, United States. Founded in 1888 by Dr. Wallace C. Abbott, the company has evolved from a traditional pharmaceutical business into a diversified healthcare platform with meaningful positions across medical technologies, diagnostics, nutrition and branded generic medicines. For international investors, Abbott is typically viewed as a high-quality large-cap healthcare name with defensive characteristics, recurring revenue streams and a long record of product innovation. Abbott’s business is organized around four main segments: Medical Devices, Diagnostics, Nutrition and Established Pharmaceuticals. Medical Devices is now the key growth engine and includes leading franchises in diabetes care, cardiovascular therapies and other intervention-focused technologies. The company’s flagship FreeStyle Libre continuous glucose monitoring system is one of the best-known products in the sector and has helped Abbott build a strong position in diabetes technology. Abbott also sells a broad set of cardiovascular and electrophysiology products, including solutions for structural heart care, rhythm management and minimally invasive procedures. Diagnostics provides laboratory and molecular testing systems, Nutrition covers adult, pediatric and specialty nutrition, and Established Pharmaceuticals sells branded generic medicines in a broad range of international markets. From a competitive standpoint, Abbott holds a strong position in several attractive healthcare niches thanks to its scale, regulatory expertise, global distribution and steady innovation pipeline. Its portfolio benefits from a combination of recurring consumable revenue, installed-base economics and relatively high barriers to entry in areas such as glucose monitoring and advanced cardiovascular devices. This makes Abbott particularly resilient compared with more cyclical industrial or consumer businesses, while still offering above-average growth potential for a mature healthcare company. Geographically, Abbott has a broad global footprint, with meaningful sales in the United States and across international markets. That diversification supports earnings stability, although it also exposes the company to foreign exchange movements and different reimbursement and regulatory regimes. Recent company disclosures point to solid operational momentum: Abbott reported strong 2025 results, with growth led by Medical Devices and its base business, and it issued 2026 guidance reflecting continued expansion. In 2026, Abbott also announced the acquisition of Exact Sciences, which materially strengthens its diagnostics platform and expands its exposure to cancer screening and early detection. Overall, Abbott remains one of the most established healthcare franchises on the market, combining scale, innovation and long-term earnings quality.
